ATP13A1 Activators
ATP13A1 Activators encompass a spectrum of chemical compounds that directly or indirectly promote the activation of ATP13A1, a P-type ATPase that plays a critical role in cation transport across cellular membranes. These activators engage with ATP13A1 by manipulating the protein's phosphorylation state, interacting with regulatory proteins, or by altering the ionic environment within the cell to necessitate the increased activity of ATP13A1. For instance, sodium orthovanadate ensures ATP13A1 remains in a phosphorylated state, a prerequisite for its activation. In contrast, Calmidazolium chloride blocks the interaction of ATP13A1 with calmodulin, a regulatory protein that could inhibit ATP13A1's activity, thereby ensuring that ATP13A1 remains active.
Moreover, certain compounds like Valinomycin, FCCP, and Monensin disrupt ionic gradients by inhibiting ion pumps or forming ion channels, which leads to an imbalanced cellular ionic environment. Under these conditions, ATP13A1's activity may be upregulated as a compensatory response to restore ion homeostasis. Similarly, the disturbance in calcium handling due to Cyclopiazonic acid and Nitrendipine could lead to an indirect enhancement of ATP13A1's activity, as the protein might be involved in the homeostatic response to these perturbations. Each activator, through its unique interaction with cellular pathways, ensures that ATP13A1 activity is upregulated, thereby sustaining the vital cation transport necessary for various physiological processes including neuronal function, intracellular signaling, and maintenance of cellular ion balance. The modulation of ATP13A1 activity by these activators is of particular interest in the field of neurodegenerative diseases, where altered metal ion homeostasis is a common feature.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $49.00 $57.00 $187.00 | 142 | |
Sodium orthovanadate is a phosphatase inhibitor that can prevent the dephosphorylation of proteins. Since ATP13A1 is a P-type ATPase involved in cation transport, inhibition of phosphatases can lead to a sustained phosphorylated state of ATP13A1, which is necessary for its activation cycle. | ||||||
Calmidazolium chloride | 57265-65-3 | sc-201494 sc-201494A | 10 mg 50 mg | $156.00 $612.00 | 27 | |
Calmidazolium chloride is a calmodulin antagonist. ATP13A1's activity is potentially regulated by calcium/calmodulin-dependent processes. By inhibiting calmodulin, calmidazolium chloride could enhance ATP13A1 activity by preventing the inhibition that would normally be mediated by calmodulin binding. | ||||||
Valinomycin | 2001-95-8 | sc-200991 | 25 mg | $250.00 | 3 | |
Valinomycin is a potassium ionophore that can disrupt potassium gradients across membranes. This disruption can indirectly enhance ATP13A1 activity as it may compensate for ionic imbalances created by altered potassium levels. | ||||||
FCCP | 370-86-5 | sc-203578 sc-203578A | 10 mg 50 mg | $94.00 $355.00 | 46 | |
FCCP is a protonophore that collapses proton gradients across membranes. The resultant disruption in proton homeostasis can enhance ATP13A1 activity as the protein may work to restore ion balance. | ||||||
Nitrendipine | 39562-70-4 | sc-201466 sc-201466A sc-201466B | 50 mg 100 mg 500 mg | $109.00 $160.00 $458.00 | 6 | |
Nitrendipine is a calcium channel blocker that can alter intracellular calcium levels. Changes in calcium dynamics may enhance ATP13A1 activity if ATP13A1 is involved in calcium regulation or compensation mechanisms. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Zinc pyrithione is known to modulate ion channels and transporters. By altering the function of other metal ion transporters, it could enhance the activity of ATP13A1 by compensatory mechanisms that maintain metal ion homeostasis. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
Cyclopiazonic acid is also a SERCA pump inhibitor. By disrupting calcium storage and increasing cytosolic calcium, it may enhance ATP13A1 activity in a similar fashion to thapsigargin, by compensating for calcium balance. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is a sodium ionophore that disrupts sodium homeostasis. The resultant sodium imbalance could enhance ATP13A1 activity as part of a compensatory response to maintain ionic equilibrium. | ||||||